NCT04202705View on ClinicalTrials.gov

A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate SYD1875

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

February 28, 2020

Primary Completion Date

June 22, 2022

Study Completion Date

January 26, 2023

Conditions
Solid Tumor
Interventions
DRUG

SYD1875

SYD1875 IV (in the vein) infusion every three weeks. Number of cycles: until cancer progression or unacceptable toxicity develops. Different doses.

Trial Locations (3)

Unknown

Institut Jules Bordet, Brussels

Institut Bergonié, Bordeaux

Centre Oscar Lambret, Lille

Sponsors

Lead Sponsor

Byondis B.V.
All Listed Sponsors
lead

Byondis B.V.

INDUSTRY